PTA failures of AV graft lesions
Not indicated for use in Canada.
Percutaneous transluminal angioplasty (PTA) has significant limitations when treating Arteriovenous (AV) access lesions1
- Patency rates diminish with each successive angioplasty procedure.1,2
- In the REVISE Clinical Study, patients undergoing PTA who had a previous intervention at the target lesion had lower primary patency at six months when compared with patients with no prior interventions at the target lesion (29.2% vs. 43.9%).1
- The 2019 KDOQI guidelines for vascular access specify a target goal of ≤ three interventions annually to maintain access.3
- In support of achieving this goal, KDOQI recommends stent grafts in preference to angioplasty alone for recurrent clinically significant stenotic AV access lesions.
Before
Thrombosed left arm AV graft. 80% stenosis just past venous anastomosis.
Images courtesy of Jason Burgess, M.D. Used with permission.
After
Post-placement of 7 mm x 5 cm GORE® VIABAHN® Endoprosthesis.
Images courtesy of Jason Burgess, M.D. Used with permission.
The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface*† has proven patency independent of the number of prior interventions1
Proven patency
- Provided consistent patency independent of the number of times a lesion has previously been treated.1
FEWER REINTERVENTIONS
- Reduced the average number of reinterventions by 27% over two years within the circuit compared to PTA.4
Stent graft design provides unique benefits to the treatment of lesions refractory to PTA
- Expanded PTFE (ePTFE) flow lumen covers and seals off diseased tissue.
AV access maintenance challenges
- The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface† has proven success in the most challenging AV access cases, including early PTA failures, lesions at points of flexion, and in thrombosed grafts.
Connect with a Gore Field Sales Associate
* As used by Gore, Heparin Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.
† Also referred to as the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface in some regions.
- Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1. http://www.sciencedirect.com/science/article/pii/S0741521416301756
- Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 1995;195(1):135-139.
- Lok CE, Huber TS, Lee T, et al; KDOQI Vascular Access Guideline Work Group. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update. American Journal of Kidney Diseases 2020;75(4)Supplement 2:S1-S164.
- Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators. Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial. Journal of Vascular & Interventional Radiology 2019;30(2):203-211.e4.
Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
22797638-EN